glp 1 noom Unboxing GLP-1ᴿˣ Noom's GLP-1 Companion Receives Major
Description
New medications under FDA review, such as dual and triple agonists, are showing 20-30% weight loss in trials, monthly dosing options, and more flexible oral formulations are all in late-stage development
While further research is warranted, current evidence supports their use as promising interventions to improve metabolic health beyond mere weight loss

, & Fodor, D
Alcohol consumption can affect glycemic control, and the combination of GLP-1 therapy with alcohol might increase hypoglycemia risk, particularly in patients taking concomitant insulin or sulfonylureas
Patients were randomized to receive Victoza 1.8 mg (n=140) or placebo (n=139) in addition to existing oral antidiabetics and/or insulin therapy
Data on kidney outcomes remain limited, but SGLT2is appear particularly effective when kidney protection is the primary goal, regardless of concurrent treatment
